Amy Jackson
Nurse Practitioner · Omaha, NENPI 1679623672
Payments from drug & device makers
Across 130 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$281
- Abbott$253
- AbbVie$225
- AstraZeneca$186
- Novo Nordisk$184
- Pfizer$184
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,38198%
- Education$392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 15 | $281 |
| Abbott | 2 | $253 |
| AbbVie | 10 | $225 |
| AstraZeneca | 12 | $186 |
| Novo Nordisk | 10 | $184 |
| Pfizer | 11 | $184 |
| Lilly USA, LLC | 10 | $177 |
| Otsuka America Pharmaceutical, Inc. | 8 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $116 |
| Mylan Specialty L.p. | 7 | $104 |
| Avanir Pharmaceuticals, Inc. | 6 | $87 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Amgen | 5 | $75 |
| Johnson & Johnson | 4 | $59 |
| Paratek Pharmaceuticals, Inc. | 3 | $47 |
| Astellas Pharma US Inc | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| GSK | 2 | $29 |
| Merck | 2 | $24 |
| Novartis | 2 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,419 in reported general payments places this provider in the 85th percentile of 924 nurse practitioner providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $71,288 |
| OzempicSemaglutide | 46 | $42,691 |
| FarxigaDapagliflozin Propanediol | 80 | $35,649 |
| MounjaroTirzepatide | 29 | $32,208 |
| LinzessLinaclotide | 48 | $28,894 |
| KerendiaFinerenone | 33 | $25,847 |
| MyrbetriqMirabegron | 71 | $22,388 |
| JardianceEmpagliflozin | 26 | $20,759 |
| JanuviaSitagliptin Phosphate | 26 | $17,145 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $17,025 |
| VraylarCariprazine Hcl | 11 | $16,000 |
| XareltoRivaroxaban | 29 | $14,955 |
| TrulicityDulaglutide | 14 | $12,784 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,402 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $5,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $184 | $71,288187 claims |
| Lilly USA, LLCMounjaro, Trulicity | $177 | $44,99243 claims |
| AbbVieLinzess, Vraylar | $225 | $44,89459 claims |
| Novo NordiskOzempic | $184 | $42,69146 claims |
| AstraZenecaFarxiga | $186 | $35,64980 claims |
| BayerKerendia | $281 | $25,84733 claims |
| Astellas Pharma US IncMyrbetriq | $39 | $22,38871 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $29 | $22,16137 claims |
| MerckJanuvia | $24 | $17,14526 claims |
| Johnson & JohnsonXarelto | $59 | $14,95529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 924 nurse practitioner providers in Nebraska.
Other nurse practitioner in Omaha
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Amanda GuggenmosOmaha$23K
- Amy YagerOmaha$15K
- Cara SchiesslerOmaha$14K
- Lindsay OneilOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.